Myasthenia Gravis Composite (MGC)

Burns TM; Conaway M; Sanders DB; Cutter GR


Basic description

Published in 2008


Burns TM; Conaway M; Sanders DB; Cutter GR

Muscle Study Group / MG Composite and MG-QoL15 Study Group
Public domain (according to the author)
To measure symptoms and signs of Myasthenia Gravis (MG)
Therapeutic area
  • Nervous System Diseases
  • Immune System Diseases
  • Rare disease (Orphanet definition)
Therapeutic indication

Myasthenia Gravis For more information on this rare disease, please consult the following link: Orphanet page

Type of Clinical Outcome Assessment (COA)
  • Composite
ClinRO, PerfO and PRO
Original language(s)
  • English for the USA
1 translation(s)
Bibliographic reference(s) of the original questionnaire

Burns TM, Conaway MR, Cutter GR, Sanders DB; Muscle Study Group. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve. 2008 Dec;38(6):1553-62 (Pubmed Abstract)

Burns TM, Conaway M, Sanders DB; MG Composite and MG-QOL15 Study Group. The MG Composite: A valid and reliable outcome measure for myasthenia gravis. Neurology. 2010 May 4;74(18):1434-40 (Full text article)

Sadjadi R, Conaway M, Cutter G, Sanders DB, Burns TM; MG Composite MG-QOL15 Study Group. Psychometric evaluation of the myasthenia gravis composite using Rasch analysis. Muscle Nerve. 2012 Jun;45(6):820-5 (Pubmed Abstract)

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us